Clinical trials: Adult T Cell Lymphoma (ATL)
Leukemia, Adult T-Cell
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Adult T-cell leukemia (ATL) is and aggressive characterized by the presence of cluster of differentiation 4 (CD4)/cluster of differentiation 25 (CD25)-expressing T cells (interleukin-2 [IL-2]R expressing) in the peripheral blood…
- Trial name
- NCT00117845
- Testing
- Denileukin diftitox (Ontak)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Acute T-Cell Leukemia-Lymphoma
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
This study will examine the safety and effectiveness of Alemtuzumab (Campath-1H) for treating patients with adult T-cell leukemia/lymphoma (ATL).
- Trial name
- NCT00061048
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Malignant, Non-hodgkin Lymphoma
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to…
- Trial name
- NCT02732275
- Testing
- DS-3201b
- Where
- 20 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Adult T Cell Leukemia, Adult T Cell Lymphoma
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
This clinical trial will be a multicenter phase II fixed-dose trial in which a minimum of 10 patients with immunophenotypically confirmed ATL with at least 50% of the blasts expressing CD25 as measured by flow cytometry at…
- Trial name
- NCT01378871
- Testing
- IMTOX-25
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amit Verma
T Cell Leukemia, Adult, Leukemia, Adult T-Cell
Ruxolitinib for Adult T-Cell Leukemia
Background: The human T-cell leukemia virus 1 (HTLV-1) causes adult T-cell leukemia (ATL). Infection does not immediately cause ATL, but it can develop over time.
- Conditions
- T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
- Trial name
- NCT01712659
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1…
- Conditions
- Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia, HTLV-1 Infection
- Trial name
- HTLV-OBS (NCT05237245)
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adult T-Cell Leukemia-Lymphoma
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.
- Trial name
- NCT01724177
- Testing
- Lenalidomide
- Where
- 18 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Celgene
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Background: Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers.
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT01087333
- Where
- United States
- Volunteers
- 1,263 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia (ATL).
- Trial name
- NCT00001249
- Testing
- Yttrium-90 radiolabeled anti-Tac antibody
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
- Trial name
- NCT00355472
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL)
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL.
- Conditions
- T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT02689453
- Testing
- IL-15 plus, alemtuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Radiation Toxicity
Monoclonal Antibody Therapy in Treating Patients With Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00019227
- Testing
- pentetic acid calcium, yttrium Y 90 daclizumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Leukemias, Acute Myeloid Leukemia (AML)
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous…
- Conditions
- Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL)
- Trial name
- NCT00664677
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Erimos Pharmaceuticals
Adult T-Cell Leukemia (ATL)
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
BACKGROUND: Cluster of differentiation 25 (CD25) (p55, Tac or interleukin 2 receptor (IL2R) alpha) is strongly expressed in virtually 100% of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human…
- Trial name
- NCT00924170
- Testing
- LMB-2, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.